View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, May 4 (HealthDay News) -- Bristol-Myers Squibb is voluntarily recalling a lot of warfarin sodium (Coumadin) 5 mg tablets after a tablet from one bottle was discovered to have a higher potency than it should, according to a safety alert posted by the U.S. Food and Drug Administration.
Too much active ingredient in the drug could increase the risk of bleeding, while too little could result in the development of blood clots, increasing the risk of heart attack or stroke. The lot in question is 9H49374A with an expiration date of Sept. 30, 2012.
Patients taking the 5 mg tablets are advised not to discontinue medication but to contact their pharmacist to determine whether their bottle came from the affected lot. If so, they should consult their physician for advice.
"Bristol-Myers Squibb is committed to ensuring patient safety and is working to resolve this issue quickly and appropriately. The company has notified the U.S. Food and Drug Administration, and will issue recall communications to all physicians and other customers involved," according to the FDA release.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top